Service des maladies infectieuses

Equipe principale
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


2452 publications

... | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | ...
2007
 
CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy
Wolbers M., Battegay M., Hirschel B., Furrer H., Cavassini M., Hasse B., Vernazza P. L., Bernasconi E., Kaufmann G., Bucher H. C., 2007. Antiviral Therapy, 12 (6) pp. 889-97.
[WoS][Pmid][serval:BIB_095EBD1F8CCB]
 
Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation.
Manuel O., Humar A., Preiksaitis J., Doucette K., Shokoples S., Peleg A.Y., Cobos I., Kumar D., 2007. American Journal of Transplantation, 7 (12) pp. 2797-2801. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_211E57E60B87]
 
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
Arnedo M., Taffé P., Sahli R., Furrer H., Hirschel B., Elzi L., Weber R., Vernazza P., Bernasconi E., Darioli R. et al., 2007. Pharmacogenetics and Genomics, 17 (9) pp. 755-764. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E06BA0A2D35]
 
Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites.
Bondeva T., Roger T., Wolf G., 2007. American Journal of Nephrology, 27 (3) pp. 308-314.
[DOI][WoS][Pmid][serval:BIB_1F5837DADABB]
 
Early-Onset Pro-inflammatory Cytokines in Sepsis.
Kaech C, Calandra T, 2007. pp. - dans Kaech C, Calandra T (eds.) Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery chap. -, Springer Berlin Heidelberg.
[serval:BIB_BFD28CAEF282]
Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation.
Manuel O., Venetz J.P., Fellay J., Wasserfallen J.B., Sturzenegger N., Fontana M., Matter M., Meylan P.R., Pascual M., 2007. Swiss Medical Weekly, 137 (47-48) pp. 669-676. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_ADD96A40C95B]
 
Empirical antifungal therapy in neutropaenic cancer patients with persistent fever
Marchetti O., Cordonnier C., Calandra T., 2007. European Journal of Cancer. Supplement, 5 (2) pp. 32-42.
[DOI][WoS][serval:BIB_ACBE350E603C]
 
Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia
Cometta A., Marchetti O., Calandra T., 2007. European Journal of Cancer. Supplement, 5 (2) pp. 23-31.
[DOI][WoS][serval:BIB_D816F555A3A2]
 
Exhaustion is associated with low macrophage migration inhibitory factor expression in patients with coronary artery disease
Kwaijtaal M., van der Ven A. J., van Diest R., Bruggeman C. A., Bar F. W., Calandra T., Appels A., Sweep F. C., 2007/01. Psychosomatic Medicine, 69 (1) pp. 68-73.
[DOI][WoS][Pmid][serval:BIB_2C76C0E9BD79]
 
Highlights de la CROI
Cavassini M, 2007. Haus-Arzt Praxis - AIDS special Springer-Medizin.
[serval:BIB_32446A4F5935]
 
Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy
Wunder D. M., Bersinger N. A., Fux C. A., Mueller N. J., Hirschel B., Cavassini M., Elzi L., Schmid P., Bernasconi E., Mueller B. et al., 2007. Antiviral Therapy, 12 (2) pp. 261-5.
[WoS][Pmid][serval:BIB_D47EB9F3C085]
Innate immunogenetics: a tool for exploring new frontiers of host defence.
Bochud P.Y., Bochud M., Telenti A., Calandra T., 2007. Lancet Infectious Diseases, 7 (8) pp. 531-542. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1861A7E7704C]
 
L'interniste chef de service de médecine interne générale d'un hôpital périphérique: une espèce en danger [The chief internist of the general internal medicine department of a regional hospital: an endangered species?].
Baumgartner J.D., Cometta A., Fumeaux T., 2007. Revue Médicale Suisse, 3 (133) pp. 2579-2580.
[Pmid][serval:BIB_B738C4AE3C35]
 
MIF in innate immunity and infectious diseases
Kaech C., Roger T., Calandra T. , 2007. p. 3 dans Bucala R. (eds.) MIF: a most interesting factor, World Scientific Publishing Co.
[serval:BIB_9D44D212E386]
 
MIF in innate immunity and infectious diseases.
Kaech C, Roger T, Calandra T, 2007. pp. - dans Bucala R (eds.) MIF: a most interesting factor chap. -, World Scientific Publishing.
[serval:BIB_2662982DE9A5]
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
Weder W., Stahel R.A., Bernhard J., Bodis S., Vogt P., Ballabeni P., Lardinois D., Betticher D., Schmid R., Stupp R. et al., 2007. Annals of Oncology, 18 (7) pp. 1196-1202. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2F98A8407C41]
 
Méningo-encéphalite verno-estivate dans le Nord vaudois [Tick-borne encephalitis in the North part of the canton de Vaud].
Schlaefli R., Randin D., Wyss P., de Vallière S., Meylan P., Cometta A., 2007. Revue Médicale Suisse, 3 (133) pp. 2609-2613.
[Pmid][serval:BIB_F75E2B78A9ED]
 
Neuromyelitis optica following CMV primo-infection.
Tran C., Du Pasquier R.A., Cavassini M., Guex-Crosier Y., Meuli R., Ciuffreda D., Waeber G., 2007. Journal of Internal Medicine, 261 (5) pp. 500-503. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13451DE0B788]
 
Oral valganciclovir for cytomegalovirus colitis after liver transplantation.
Manuel O., Meylan P.R., Rotman S., Fontana M., Moradpour D., Pascual M., 2007. Transplantation, 83 (2) pp. 239-240. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_608297CF0B7D]
 
Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection.
Bochud P.Y., Magaret A.S., Koelle D.M., Aderem A., Wald A., 2007. Journal of Infectious Diseases, 196 (4) pp. 505-509. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_908B8C88A91A]
 
Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection.
Bochud P.Y., Hersberger M., Taffé P., Bochud M., Stein C.M., Rodrigues S.D., Calandra T., Francioli P., Telenti A., Speck R.F. et al., 2007. AIDS, 21 (4) pp. 441-446. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DD623A3A316D]
Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission
Elzi L., Schlegel M., Weber R., Hirschel B., Cavassini M., Schmid P., Bernasconi E., Rickenbach M., Furrer H., 2007/01. Clinical Infectious Diseases, 44 (1) pp. 94-102.
[URN][DOI][WoS][Pmid][serval:BIB_23B13C5E19B9]
 
Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression.
Roger T., Ding X., Chanson A.L., Renner P., Calandra T., 2007. European Journal of Immunology, 37 (12) pp. 3509-3521. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_05823E3002EA]
 
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Fux C.A., Simcock M., Wolbers M., Bucher H.C., Hirschel B., Opravil M., Vernazza P., Cavassini M., Bernasconi E., Elzi L. et al., 2007. Antiviral Therapy, 12 (8) pp. 1165-1173. Peer-reviewed.
[WoS][Pmid][serval:BIB_1FF1C058E28E]
 
Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
Tarr P.E., Telenti A., 2007. Antiviral Therapy, 12 (7) pp. 999-1013.
[WoS][Pmid][serval:BIB_AC4C18544415]
 
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A., Nieth V., Calandra T., Bille J., Bolay S., Decosterd L.A., Buclin T., Majcherczyk P.A., Sanglard D., Marchetti O., 2007. Antimicrobial Agents and Chemotherapy, 51 (1) pp. 137-143.
[DOI][WoS][Pmid][serval:BIB_62560DA1D073]
2006
Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study
Franceschi S., Polesel J., Rickenbach M., Dal Maso L., Probst-Hensch N. M., Fux C., Cavassini M., Hasse B., Kofler A., Ledergerber B. et al., 2006/12. British Journal of Cancer, 95 (11) pp. 1598-602.
[URN][DOI][WoS][Pmid][serval:BIB_552C347CF4FA]
 
Histone acetyltransferase HBO1 inhibits NF-kappaB activity by coactivator sequestration
Contzler R., Regamey A., Favre B., Roger T., Hohl D., Huber M., 2006/11. Biochemical and Biophysical Research Communications, 350 (1) pp. 208-13.
[DOI][WoS][Pmid][serval:BIB_D8925C4B9B42]
 
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Colombo S., Buclin T., Cavassini M., Decosterd L. A., Telenti A., Biollaz J., Csajka C., 2006/11. Antimicrobial Agents and Chemotherapy, 50 (11) pp. 3801-8.
[DOI][WoS][Pmid][serval:BIB_B3F88281E351]
 
Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation.
Erard V., Guthrie K.A., Riddell S., Boeckh M., 2006/10. Haematologica, 91 (10) pp. 1377-1383. Peer-reviewed.
[WoS][Pmid][serval:BIB_ACD66A17C547]
 
MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis
Popa C., van Lieshout A. W., Roelofs M. F., Geurts-Moespot A., van Riel P. L., Calandra T., Sweep F. C., Radstake T. R., 2006/10. Cytokine, 36 (1-2) pp. 51-6.
[DOI][WoS][Pmid][serval:BIB_E2CEE6DCFE04]
 
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Glass T. R., Ungsedhapand C., Wolbers M., Weber R., Vernazza P. L., Rickenbach M., Furrer H., Bernasconi E., Cavassini M., Hirschel B. et al., 2006/09. HIV Medicine, 7 (6) pp. 404-10.
[DOI][WoS][Pmid][serval:BIB_660672D05879]
 
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
Ananworanich J., Gayet-Ageron A., Le Braz M., Prasithsirikul W., Chetchotisakd P., Kiertiburanakul S., Munsakul W., Raksakulkarn P., Tansuphasawasdikul S., Sirivichayakul S. et al., 2006/08. Lancet, 368 (9534) pp. 459-65.
[DOI][WoS][Pmid][serval:BIB_C2BF0939C6DA]
In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients
Cometta A., Marchetti O., Calandra T., Bille J., Kern W. V., Zinner S., 2006/08. European Journal of Clinical Microbiology and Infectious Diseases, 25 (8) pp. 537-40.
[URN][DOI][WoS][Pmid][serval:BIB_C7CA4544A058]
Treatment options of invasive fungal infections in adults.
Flückiger U., Marchetti O., Bille J., Eggimann P., Zimmerli S., Imhof A., Garbino J., Ruef C., Pittet D., Täuber M. et al., 2006/07/22. Swiss medical weekly, 136 (29-30) pp. 447-463. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_B671A5617F0E]
 
Etat fébrile et Hépatosplénomégalie chez une femme de 25 ans: approche diagnostique [A 25-year-old woman with fever and hepatosplenomegaly: diagnostic approach]
Lamoth F., Chabanel D., Waeber G., 2006/07/05. Praxis, 95 (27-28) pp. 1081-1084. Peer-reviewed.
[Pmid][serval:BIB_099EF59845E1]
 
Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy.
Bertschy S., Opravil M., Cavassini M., Bernasconi E., Schiffer V., Schmid P., Flepp M., Chave J.P., Christen A., Furrer H., 2006/07. Clinical Microbiology and Infection, 12 (7) pp. 666-671. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D88DAC6C417D]
 
Les kystes lymphoepitheliaux de la glande parotide: une pathologie liee a l'infection VIH. [Lymphoepithelial cysts of the parotid gland: a pathology linked to HIV infection]
Senn N., Bron L., Cavassini M., 2006/05. Revue Médicale Suisse, 2 (66) pp. 1348-50, 1352.
[Pmid][serval:BIB_EFB753298F6C]
 
Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity
Lue H., Kapurniotu A., Fingerle-Rowson G., Roger T., Leng L., Thiele M., Calandra T., Bucala R., Bernhagen J., 2006/05. Cellular Signalling, 18 (5) pp. 688-703.
[DOI][WoS][Pmid][serval:BIB_34EA77FC28E0]
 
Sepsis severe et choc septique. [Severe sepsis and septic shock]
Delaloye J., Baumgartner J. D., Calandra T., 2006/04. Revue Médicale Suisse, 2 (60) pp. 896-8, 900-2.
[Pmid][serval:BIB_0415EFEB9B73]
 
VIH-sida: reponses a de nouvelles questions. [HIV-AIDS: answers to new questions]
Fellay J., Cavassini M., 2006/04. Revue Médicale Suisse, 2 (60) pp. 912-7.
[Pmid][serval:BIB_075785BCC2A4]
HIV and solid organ transplantation: the Swiss experience.
Müller N.J., Furrer H., Kaiser L., Hirschel B., Cavassini M., Fellay J., Chave J.P., Wüthrich R.P., Weber M., Müllhaupt B. et al., 2006/03/18. Swiss medical weekly, 136 (11-12) pp. 194-196. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_193786587693]
 
Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study
Glass T. R., De Geest S., Weber R., Vernazza P. L., Rickenbach M., Furrer H., Bernasconi E., Cavassini M., Hirschel B., Battegay M. et al., 2006/03. Journal of Acquired Immune Deficiency Syndromes, 41 (3) pp. 385-92.
[DOI][WoS][Pmid][serval:BIB_013B48DAB2A3]
 
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
Viscoli C., Cometta A., Kern W.V., Bock R., Paesmans M., Crokaert F., Glauser M.P., Calandra T., International Antimicrobial Therapy Group of the European Organization for Research, Treatment of Cancer, 2006/03. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 12 (3) pp. 212-216. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C865C2384022]
 
Angiotensin II upregulates toll-like receptor 4 on mesangial cells.
Wolf G., Bohlender J., Bondeva T., Roger T., Thaiss F., Wenzel U.O., 2006. Journal of the American Society of Nephrology : Jasn, 17 (6) pp. 1585-1593.
[DOI][WoS][Pmid][serval:BIB_37AB51EADBB3]
Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species.
Senn L., Entenza J.M., Greub G., Jaton K., Wenger A., Bille J., Calandra T., Prod'hom G., 2006. BMC Infectious Diseases, 6 (9) pp. 1-6.
[URN][DOI][WoS][Pmid][serval:BIB_60E04201075E]
 
Chronic rhinoviral infection in lung transplant recipients.
Kaiser L., Aubert J.D., Pache J.C., Deffernez C., Rochat T., Garbino J., Wunderli W., Meylan P., Yerly S., Perrin L. et al., 2006. American Journal of Respiratory and Critical Care Medicine, 174 (12) pp. 1392-1399. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_58FD275DD194]
 
Corticotropin-releasing factor and the urocortins induce the expression of TLR4 in macrophages via activation of the transcription factors PU.1 and AP-1.
Tsatsanis C., Androulidaki A., Alissafi T., Charalampopoulos I., Dermitzaki E., Roger T., Gravanis A., Margioris A.N., 2006. Journal of Immunology, 176 (3) pp. 1869-1877.
[WoS][Pmid][serval:BIB_74C8564C5583]
 
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
Zinkernagel A. S., von Wyl V., Ledergerber B., Rickenbach M., Furrer H., Battegay M., Hirschel B., Tarr P. E., Opravil M., Bernasconi E. et al., 2006. Antiviral Therapy, 11 (2) pp. 131-42.
[WoS][Pmid][serval:BIB_C7B8850DE941]
 
Evidence de nouveaux foyers d'endémie de méningo-encéphalite verno-estivale en Suisse romande [Evidence of new foci of tick-borne encephalitis in the French speaking part of Switzerland].
de Vallière S., Cometta A., Zimmermann H., Vaudaux B., Meylan P., 2006. Revue Médicale Suisse, 2 (80) pp. 2189-2194.
[Pmid][serval:BIB_2E0FA41F5449]
 
First case of bacteremia and multifocal cellulitis due to Helicobacter canis in an immunocompetent patient.
Leemann C., Gambillara E., Prod'hom G., Jaton K., Panizzon R., Bille J., Francioli P., Greub G., Laffitte E., Tarr P.E., 2006. Journal of Clinical Microbiology, 44 (12) pp. 4598-4600. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_011E9B575A8D]
 
Module 8.8.15
Kaech C., Bochud P.Y., Calandra T., 2006. pp. Module 8.8.15 dans Kaech C., Bochud P.Y., Calandra T. (eds.) Cytokines and Escherichia coli Sepsis, Ferric Fang and Martin Kagnoff.
[serval:BIB_446A12B4706C]
 
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
Colombo S., Buclin T., Franc C., Guignard N., Khonkarly M., Tarr P. E., Rochat B., Biollaz J., Telenti A., Decosterd L. A. et al., 2006. Antiviral Therapy, 11 (1) pp. 53-62.
[WoS][Pmid][serval:BIB_B50E136DB0CD]
Tumour necrosis factor-alpha up-regulates macrophage migration inhibitory factor expression in endometrial stromal cells via the nuclear transcription factor NF-kappaB.
Cao W.G., Morin M., Sengers V., Metz C., Roger T., Maheux R., Akoum A., 2006. Human Reproduction (oxford, England), 21 (2) pp. 421-428.
[URN][DOI][WoS][Pmid][serval:BIB_138741830708]
2005
Coxiella burnetii vascular graft infection.
Senn L., Franciolli M., Raoult D., Moulin A., Von Segesser L., Calandra T., Greub G., 2005/12/07. BMC infectious diseases, 5 p. 109. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18CBECC11476]
 
Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1
Roger T., Chanson A. L., Knaup-Reymond M., Calandra T., 2005/12. European Journal of Immunology, 35 (12) pp. 3405-13.
[DOI][WoS][Pmid][serval:BIB_D7B5E76087E9]
Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases
Renner P., Roger T., Calandra T., 2005/11. Clinical Infectious Diseases, 41 Suppl 7 pp. S513-9.
[URN][DOI][WoS][Pmid][serval:BIB_5A232E2AFB66]
 
Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor
Radstake T. R., Sweep F. C., Welsing P., Franke B., Vermeulen S. H., Geurts-Moespot A., Calandra T., Donn R., van Riel P. L., 2005/10. Arthritis and Rheumatism, 52 (10) pp. 3020-9.
[DOI][WoS][Pmid][serval:BIB_B62CD92B785F]
Enhancement of Innate and Cell-Mediated Immunity by Antimycobacterial Antibodies
de valliere S., Abate G., Blazevic A., Heuertz R. M., Hoft D. F., 2005/10. Infection and Immunity, 73 (10) pp. 6711-6720.
[URN][DOI][WoS][Pmid][serval:BIB_536613950D03]
 
Changing face of health-care associated fungal infections.
Bille J., Marchetti O., Calandra T., 2005/08. Current Opinion in Infectious Diseases, 18 (4) pp. 314-319. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F26B68B9E05F]
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
Kaufmann G.R., Furrer H., Ledergerber B., Perrin L., Opravil M., Vernazza P., Cavassini M., Bernasconi E., Rickenbach M., Hirschel B. et al., 2005/08. Clinical Infectious Diseases, 41 (3) pp. 361-72.
[URN][DOI][WoS][Pmid][serval:BIB_39387EBFA26D]
 
Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum
Marshall J. C., Vincent J. L., Guyatt G., Angus D. C., Abraham E., Bernard G., Bombardier C., Calandra T., Jorgensen H. S., Sylvester R. et al., 2005/08. Critical Care Medicine, 33 (8) pp. 1708-16.
[DOI][WoS][Pmid][serval:BIB_C598F2A76D44]
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study
Rauch A., Rickenbach M., Weber R., Hirschel B., Tarr P. E., Bucher H. C., Vernazza P., Bernasconi E., Zinkernagel A. S., Evison J. et al., 2005/08. Clinical Infectious Diseases, 41 (3) pp. 395-402.
[URN][DOI][WoS][Pmid][serval:BIB_2A99567A66CD]
 
The international sepsis forum consensus conference on definitions of infection in the intensive care unit
Calandra T., Cohen J., 2005/07. Critical Care Medicine, 33 (7) pp. 1538-48.
[DOI][WoS][Pmid][serval:BIB_1E134EA47365]
 
Macrophage migration inhibitory factor reduces the growth of virulent Mycobacterium tuberculosis in human macrophages
Oddo M., Calandra T., Bucala R., Meylan P. R., 2005/06. Infection and Immunity, 73 (6) pp. 3783-6.
[DOI][WoS][Pmid][serval:BIB_FEA7D10E27FF]
 
Necrose du segment anterieur sur keratomycose a Fusarium polyresistant. A propos d'un cas. [Anterior segment necrosis in multidrug-resistant Fusarium keratomycosis: a case study]
Gianoli F., Guex-Crosier Y., Marchetti O., Wolfensberger T. J., Spahn B., 2005/05. Journal Français d'Ophtalmologie, 28 (5) pp. 498-501.
[DOI][WoS][Pmid][serval:BIB_3322031439F8]
 
VIH et voyage [HIV and travel].
D'Acremont V., Cavassini M.L., Tarr P.E., Genton B., 2005/05. Revue Médicale Suisse, 1 (19) pp. 1268-1274.
[Pmid][serval:BIB_4E94A1970C07]
 
Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy
Hornberger J., Green J., Wintfeld N., Cavassini M., Rockstroh J., Giuliani G., De Carli C., Lazzarin A., 2005/04. HIV Clinical Trials, 6 (2) pp. 92-102.
[WoS][Pmid][serval:BIB_12F79A29BACA]
 
Utilite de la procalcitonine dans le diagnostic et le suivi des infections chez les patients neutropeniques febriles. [Utility of procalcitonin for the diagnosis and the follow-up of infections in febrile neutropenic patients]
Robinson J. O., Calandra T., Marchetti O., 2005/03. Revue Médicale Suisse, 1 (13) pp. 878-82, 885-6.
[Pmid][serval:BIB_6FD19B7CD714]
A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer
Akova M., Paesmans M., Calandra T., Viscoli C., 2005/01. Clinical Infectious Diseases, 40 (2) pp. 239-45.
[URN][DOI][WoS][Pmid][serval:BIB_922723DB4E7A]
 
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
Young J., Rickenbach M., Weber R., Furrer H., Bernasconi E., Hirschel B., Tarr P. E., Vernazza P., Battegay M., Bucher H. C., 2005. Antiviral Therapy, 10 (1) pp. 73-81.
[WoS][Pmid][serval:BIB_F234AB2FD71E]
 
Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression.
Roger T., Miconnet I., Schiesser A.L., Kai H., Miyake K., Calandra T., 2005. The Biochemical journal, 387 (Pt 2) pp. 355-65.
[DOI][WoS][Pmid][serval:BIB_B353B81B94B3]
 
Cryptococcose disseminée: Manifestation inaugurale d'un SIDA [Disseminated cryptococcosis as inaugural manifestation of AIDS]
Fournier Y., Bellini C., Baur A.S., Waeber G., Cavassini M., 2005. Praxis, 94 (1-2) pp. 17-23.
[Pmid][serval:BIB_A5FFF4410D85]
 
Diarrhées infectieuses [Infectious diarrhea].
Mottet C., El Wafa A.A., Cavassini M., D'Acremont V., Delarive J., 2005. Revue Médicale Suisse, 1 (3) pp. 209-217.
[Pmid][serval:BIB_C76A825ECCC5]
 
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
Karrer U., Ledergerber B., Furrer H., Elzi L., Battegay M., Cavassini M., Gayet-Ageron A., Hirschel B., Schmid P., Russotti M. et al., 2005. Aids, 19 (17) pp. 1987-1994.
[DOI][WoS][Pmid][serval:BIB_5012641E36D5]
 
Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies.
Prella M., Bille J., Pugnale M., Duvoisin B., Cavassini M., Calandra T., Marchetti O., 2005. Diagnostic Microbiology and Infectious Disease, 51 (2) pp. 95-101. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_36702]
Efavirenz intoxication due to slow hepatic metabolism
Hasse B., Günthard H.F., Bleiber G., Krause M., 2005. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 40 (3) pp. e22-e23.
[URN][DOI][WoS][Pmid][serval:BIB_94D5173C4402]
 
Emerging viral infections after hematopoietic cell transplantation.
Boeckh M., Erard V., Zerr D., Englund J., 2005. Pediatric Transplantation, 9 (Suppl. 7) pp. 48-54. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E43C76C4A53D]
How critical is timing for the diagnosis of influenza in general practice?
Senn N., Favrat B., D'Acremont V., Ruffieux C., Genton B., 2005. Swiss Medical Weekly, 135 (41-42) pp. 614-617. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_B919E2FA4C17]
 
Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists.
Eggimann P., Calandra T., Fluckiger U., Bille J., Garbino J., Glauser M.P., Marchetti O., Ruef C., Täuber M., Pittet D., 2005. Intensive care medicine, 31 (11) pp. 1514-21. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A18308CBA34A]
 
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
Young J., Weber R., Rickenbach M., Furrer H., Bernasconi E., Hirschel B., Tarr P. E., Vernazza P., Battegay M., Bucher H. C., 2005. Antiviral Therapy, 10 (5) pp. 585-91.
[WoS][Pmid][serval:BIB_2CA99B7FC263]
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
Tarr P.E., Taffé P., Bleiber G., Furrer H., Rotger M., Martinez R., Hirschel B., Battegay M., Weber R., Vernazza P. et al., 2005. Journal of Infectious Diseases, 191 (9) pp. 1419-1426. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_811D1E662350]
 
Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers.
Cavassini M.L., D'Acremont V., Furrer H., Genton B., Tarr P.E., 2005. Expert Opinion on Pharmacotherapy, 6 (6) pp. 891-913.
[DOI][WoS][Pmid][serval:BIB_8B6D6344F47A]
 
Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy.
Wunder D., Bersinger N.A., Fux C., Weber R., Bernasconi E., Cavassini M., Bucher H.C., Schiffer V., Schmid P., Furrer H. et al., 2005. Aids, 19 (16) pp. 1837-1842.
[DOI][WoS][Pmid][serval:BIB_5AF92BC67164]
 
Staphylococcus aureus (Including Staphylococcal Toxic Shock)
Moreillon P., Que Y. A., Glauser M. P., 2005. pp. 2321-2351 dans Mandell G. L., Bennett J. E., Dolin R. (eds.) Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases chap. 192, Churchill Livingstone.
[serval:BIB_6B91BDA512E8]
 
Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.
Fellay J., Venetz J.P., Aubert J.D., Seydoux C., Pascual M., Meylan P.R., 2005. Transplantation Proceedings, 37 (2) pp. 949-951. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_78A1B0521279]
 
Treatment of dyslipidaemia in HIV-infected persons.
Manuel O., Thiébaut R., Darioli R., Tarr P.E., 2005. Expert Opinion on Pharmacotherapy, 6 (10) pp. 1619-1645. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_504A35989DEB]
2004
 
Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review
Bochud P. Y., Bonten M., Marchetti O., Calandra T., 2004/11. Critical Care Medicine, 32 (11 Suppl) pp. S495-512.
[Pmid][serval:BIB_E620137692A7]
 
Exaggerated IL-8 and IL-6 responses to TNF-alpha by parainfluenza virus type 4-infected NCI-H292 cells.
Roger T., Bresser P., Snoek M., van der Sluijs K., van den Berg A., Nijhuis M., Jansen H.M., Lutter R., 2004/11. American Journal of Physiology. Lung Cellular and Molecular Physiology, 287 (5) pp. L1048-1055. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C07CF5FF419]
Clinical trials of antifungal prophylaxis among patients undergoing surgery
Calandra T., Marchetti O., 2004/10. Clinical Infectious Diseases, 39 Suppl 4 pp. S185-92.
[URN][DOI][WoS][Pmid][serval:BIB_3DAF04C7A706]
 
Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study
Zellweger C., Opravil M., Bernasconi E., Cavassini M., Bucher H. C., Schiffer V., Wagels T., Flepp M., Rickenbach M., Furrer H., 2004/10. AIDS, 18 (15) pp. 2047-53.
[DOI][WoS][Pmid][serval:BIB_E6F04B87DD48]
 
Is unsafe sexual behaviour increasing among HIV-infected individuals?
Glass T. R., Young J., Vernazza P. L., Rickenbach M., Weber R., Cavassini M., Hirschel B., Battegay M., Bucher H. C., 2004/08. AIDS, 18 (12) pp. 1707-14.
[DOI][WoS][Pmid][serval:BIB_9067282F61A8]
Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
Robatel C., Rusca M., Padoin C., Marchetti O., Liaudet L., Buclin T., 2004/07. The Journal of Antimicrobial Chemotherapy, 54 (1) pp. 269-270. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A37F4C59DB8]
 
Gynecomastia and potent antiretroviral therapy.
Strub C., Kaufmann G.R., Flepp M., Egger M., Kahlert C., Cavassini M., Battegay M., Swiss HIV Cohort Study, 2004/06/18. AIDS, 18 (9) pp. 1347-1349. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F8DDA64F4862]
 
Nouvelles strategies therapeutiques dans le sepsis severe et le choc septique. [New therapeutic strategies in severe sepsis and septic shock]
Oddo M., Schaller M. D., Calandra T., Liaudet L., 2004/06. Revue Médicale de la Suisse Romande, 124 (6) pp. 329-32.
[Pmid][serval:BIB_C9083C3A5B0A]
 
Hematogenous enterococcal vertebral osteomyelitis: report of 2 cases and review of the literature
Tarr P. E., Sakoulas G., Ganesan A., Smith M. A., Lucey D. R., 2004/05. Journal of Infection, 48 (4) pp. 354-62. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EF05810C5C14]
 
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
Kaufmann G. R., Khanna N., Weber R., Perrin L., Furrer H., Cavassini M., Ledergerber B., Vernazza P., Bernasconi E., Rickenbach M. et al., 2004/04. Antiviral Therapy, 9 (2) pp. 263-74.
[WoS][Pmid][serval:BIB_E779951187D8]
 
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
Dellinger R. P., Carlet J. M., Masur H., Gerlach H., Calandra T., Cohen J., Gea-Banacloche J., Keh D., Marshall J. C., Parker M. M. et al., 2004/03. Critical Care Medicine, 32 (3) pp. 858-73.
[DOI][WoS][Pmid][serval:BIB_91CEBCB88D7D]
 
Traitement antibiotique oral des neutropenies febriles en onco-hematologie. L'experience du groupe antimicrobien de l'EORTC. [Treatment with oral antibiotics of febrile neutropenia in onco-haematology. The experience of the EORTC antimicrobial group]
Cometta A., Kern W., 2004/03. Presse Médicale, 33 (5) pp. 327-9.
[DOI][WoS][Pmid][serval:BIB_67BB6D268DE0]
Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000
Marchetti O., Bille J., Fluckiger U., Eggimann P., Ruef C., Garbino J., Calandra T., Glauser M. P., Tauber M. G., Pittet D., 2004/02. Clinical Infectious Diseases, 38 (3) pp. 311-20.
[URN][DOI][WoS][Pmid][serval:BIB_182048CCAD71]
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Erard V., Lamy O., Bochud P.Y., Bille J., Cometta A., Calandra T., 2004/02. European Journal of Clinical Microbiology & Infectious Diseases, 23 (2) pp. 82-88. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E3C795740BC3]
MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment
Bleiber G., May M., Suarez C., Martinez R., Marzolini C., Egger M., Telenti A., 2004/02. Journal of Infectious Diseases, 189 (4) pp. 583-6.
[URN][DOI][WoS][Pmid][serval:BIB_4344DC6AC930]
 
Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy.
Guyot S., Hayoz D., Telenti A., Cavassini M., 2004/01/23. AIDS, 18 (2) pp. 356-358. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F7DCFAF6D84C]
 
APOBEC3G genetic variants and their influence on the progression to AIDS.
An P., Bleiber G., Duggal P., Nelson G., May M., Mangeat B., Alobwede I., Trono D., Vlahov D., Donfield S. et al., 2004. Journal of virology, 78 (20) pp. 11070-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F42175272A94]
 
Bereit für neue medizinische Herausforderungen - die Genetics HIV Cohort der Schweizerischen HIV Kohortenstudie.
Furrer H, Telenti A, 2004. Therapeut Umschau, 61 pp. 613-18.
[serval:BIB_32361]
 
Can we describe the epidemiology of candidemia without using selective blood culture bottles for fungus detection?
Tattevin P., Chevrier S., Gangneux J.P., 2004. Clinical Infectious Diseases, 39 (4) pp. 598-599; author reply 599.
[DOI][WoS][Pmid][serval:BIB_E1023B43F9D0]
 
CCTT-repreat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis.
Hersberger M, Bonhoeffer S, Rampini S, Opravil M, Marti J, Telenti A, Haenseler E, Ledergerber B, Speck R, 2004. Clinical and Experimental Immunology, 137 pp. 566-569.
[serval:BIB_32344]
Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef
Fischer M., Joos B., Hirschel B., Bleiber G., Weber R., Günthard H.F., Swiss HIV Cohort Study, 2004. Journal of Infectious Diseases, 190 (11) pp. 1979-1988.
[URN][DOI][WoS][Pmid][serval:BIB_A06B4AC25E63]
 
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
Wasserfallen J.B., Erard V., Cometta A., Calandra T., Lamy O., 2004. European Respiratory Journal, 24 (4) pp. 644-648. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_44CAE0FECC56]
 
CYP3A activity is not related to 3435C>T polymorphism in the MDR1 gene in HIV infected patients and in healthy individuals.
Eap CB, Fellay J, Buclin T, Bleiber G, Powell Golay T, Brocard M, Baumann P, Telenti A, 2004. Pharmacogenetics, 14 pp. 1-6.
[serval:BIB_32330]
 
Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
Entenza J.M., Vouillamoz J., Glauser M.P., Moreillon P., 2004. Antimicrobial Agents and Chemotherapy, 48 (1) pp. 86-92.
[DOI][WoS][Pmid][serval:BIB_7DFA6F28A1CF]
 
Endocardite infectieuse: mise au point [Infective endocarditis: update]
Que Y.A., Oddo M., Liaudet L., Moreillon P., 2004. Revue Médicale de la Suisse Romande, 124 (6) pp. 341-346.
[Pmid][serval:BIB_EB81A89C11B6]
 
Enhanced binding of processed Nef (58-206) compared to full length Nef with virion proteins of HIV-1.
Ciuffi A, Munoz M, Bleiber G, Favre M, Auderset K, Stutz F, Telenti A, Meylan P, 2004. AIDS Res Hum Retrovir, 20 pp. 399-407.
[serval:BIB_32331]
Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection.
Ciuffi A., Bleiber G., Muñoz M., Martinez R., Loeuillet C., Rehr M., Fischer M., Günthard H.F., Oxenius A., Meylan P. et al., 2004. Journal of virology, 78 (19) pp. 10747-54. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_92680CCF2EA7]
 
HIV susceptibility testing - time for standards.
Hill AM, Telenti A, 2004. Antivir Ther, 9 pp. 463-64.
[serval:BIB_32356]
 
HIV-1 co/super-infection in intravenous drug users.
Yerly S., Jost S., Monnat M., Telenti A., Cavassini M., Chave J.P., Kaiser L., Burgisser P., Perrin L. and , 2004. AIDS, 18 (10) pp. 1413-1421. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_83939434D025]
 
Infection VIH : dix points clefs pour la prise en charge par les praticiens
Khonkarly M.B., Merlani G., Halfon P., Bellini C., Pellet A., Kazadi K., Cavassini M., Tarr P., 2004. Médecine et Hygiène, 62 (2479) pp. 862-868.
[serval:BIB_33446]
 
Infective endocarditis.
Moreillon P., Que Y.A., 2004. Lancet, 363 (9403) pp. 139-149.
[DOI][WoS][Pmid][serval:BIB_E0EF1021F1E3]
 
Infrequent transmission of HIV-1 drug-resistant variants.
Yerly S., Jost S., Telenti A., Flepp M., Kaiser L., Chave J.P., Vernazza P., Battegay M., Furrer H., Chanzy B. et al., 2004. Antiviral therapy, 9 (3) pp. 375-84. Peer-reviewed.
[WoS][Pmid][serval:BIB_8E97B94E705E]
 
LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.
Vouillamoz J., Entenza J.M., Hohl P., Moreillon P., 2004. Antimicrobial Agents and Chemotherapy, 48 (11) pp. 4322-4327.
[DOI][WoS][Pmid][serval:BIB_DB070B6DC718]
Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?
Delaloye J., Merlani G., Petignat C., Wenger A., Zaman K., Monnerat C., Matzinger O., Beck Popovic M., Vuichard P., Ketterer N. et al., 2004. European Journal of Clinical Microbiology & Infectious Diseases, 23 (10) pp. 751-758. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F790400E5B03]
 
Polymorphisms, resistance and drug response - Beyond B-subtype HIV-1.
Telenti A, 2004. Antivir Ther, 9 p. 1.
[serval:BIB_32354]
 
Prise en charge ambulatoire des neutropénies fébriles à bas risque de complications: fiction ou réalité ?
Cometta A., Marchetti O., Bally F., Calandra T., 2004. Médecine et Hygiène, 62 (2479) pp. 855-60.
[serval:BIB_B385A99EB9E8]
Reply
Bille J., Marchetti O., Pittet D., 2004. Clinical Infectious Diseases, 39 (4) pp. 599-599.
[URN][DOI][WoS][serval:BIB_E3A1618C7B89]
 
Reply to the letter by Tattevin et al "Can we describe the epidemiology of candidemia without using selective blood culture bottles for fungus detections ? "
Bille J., Marchetti O., Pittet D., for the Fungal Infection Network of Switzerland, 2004. Clinical Infectious Diseases, 599 p. 39.
[serval:BIB_1547B2E9E6B1]
 
Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV Cohort Study.
Young J, De Geest S, Spirig R, Flepp M, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Telenti A, Vernazza P et al., 2004. BMJ, 328 pp. 1-5.
[serval:BIB_32326]
 
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., Gea-Banacloche J., Keh D., Marshall J.C., Parker M.M. et al., 2004. Intensive Care Medicine, 30 (4) pp. 536-555.
[DOI][WoS][Pmid][serval:BIB_31923]
 
The central region of HIV-1 p6 protein (Gag residues S14-I31) is dispensable for the virus in vitro.
Bleiber G, Peters S, Martinez R, Carko D, Meylan P, Telenti A, 2004. J Gen Virol, 85 pp. 929-932.
[serval:BIB_32336]
 
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study.
Felley C, Morris MA, Wonkam A, Hirschel B, Flepp M, Furrer HJ, Battegay M, Bernasconi E, Telenti A, Frossard JL, 2004. AIDS, 18 pp. 1521-1527.
[serval:BIB_32340]
 
Update of the drug resistance mutations in HIV-1.
Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demezter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A et al., 2004. Topics in HIV Medicine, 12 pp. 119-24.
[serval:BIB_32364]
2003
 
Neutropenies febriles. [Febrile neutropenia]
Bally F., Marchetti O., Cometta A., 2003/12. Revue du Praticien, 53 (19) pp. 2101-7.
[Pmid][serval:BIB_BAFCE65D2BE1]
The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor
Regamey A., Hohl D., Liu J. W., Roger T., Kogerman P., Toftgard R., Huber M., 2003/12. Journal of Experimental Medicine, 198 (12) pp. 1959-64.
[URN][DOI][WoS][Pmid][serval:BIB_1D52738E52B5]
 
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study
Zanetti G., Bally F., Greub G., Garbino J., Kinge T., Lew D., Romand J. A., Bille J., Aymon D., Stratchounski L. et al., 2003/11. Antimicrobial Agents and Chemotherapy, 47 (11) pp. 3442-7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_49B13F4C5A97]
 
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.
Ananworanich J., Nuesch R., Le Braz M., Chetchotisakd P., Vibhagool A., Wicharuk S., Ruxrungtham K., Furrer H., Cooper D., Hirschel B. et al., 2003/10/17. AIDS, 17 (15) pp. F33-7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_53DB530C5D13]
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy
Cometta A., Kern W. V., De Bock R., Paesmans M., Vandenbergh M., Crokaert F., Engelhard D., Marchetti O., Akan H., Skoutelis A. et al., 2003/08. Clinical Infectious Diseases, 37 (3) pp. 382-9.
[URN][DOI][WoS][Pmid][serval:BIB_330436096753]
 
Presente y futuro de la virologia clinica. [The present and future of clinical virology]
Telenti A., 2003/05. Enfermedades Infecciosas y Microbiologia Clinica, 21 Suppl 2 pp. 81-3.
[Pmid][serval:BIB_6F1157F2AD2E]
 
Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome
Tarr P. E., Miele P. S., Peregoy K. S., Smith M. A., Neva F. A., Lucey D. R., 2003/04. American Journal of Tropical Medicine and Hygiène, 68 (4) pp. 453-5. Peer-reviewed.
[WoS][Pmid][serval:BIB_EAB4E07CD6A6]
 
Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey
Taillard C., Greub G., Weber R., Pfyffer G. E., Bodmer T., Zimmerli S., Frei R., Bassetti S., Rohner P., Piffaretti J. C. et al., 2003/03. Journal of Clinical Microbiology, 41 (3) pp. 1240-4.
[DOI][WoS][Pmid][serval:BIB_6F22F524C924]
 
Infection urinaire et resistance aux fluoroquinolones. [Urinary tract infection and fluoroquinolone resistance]
Luisoni A., Cometta A., 2003/03. Revue Médicale de la Suisse Romande, 123 (3) pp. 155-7.
[Pmid][serval:BIB_5F5B670E96D2]
 
Mechanisms that potentially underlie virus-induced exaggerated inflammatory responses by airway epithelial cells
Lutter R., van Wissen M., Roger T., Bresser P., van der Sluijs K., Nijhuis M., Jansen H. M., 2003/03. Chest, 123 (3 Suppl) pp. 391S-2S.
[DOI][WoS][Pmid][serval:BIB_FE88BB589B11]
 
Multidrug-resistant Corynebacterium striatum pneumonia in a heart transplant recipient
Tarr P. E., Stock F., Cooke R. H., Fedorko D. P., Lucey D. R., 2003/03. Transplant Infectious Disease, 5 (1) pp. 53-8. Peer-reviewed.
[Pmid][serval:BIB_5AE0A77D1532]
 
Candida glabrata spinal osteomyelitis involving two contiguous lumbar vertebrae: a case report and review of the literature
Seravalli L., Van Linthoudt D., Bernet C., de Torrente A., Marchetti O., Porchet F., Genne D., 2003/02. Diagnostic Microbiology and Infectious Disease, 45 (2) pp. 137-41.
[DOI][WoS][Pmid][serval:BIB_CA1CEAABF534]
 
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART.
Fagard C, Le Braz M, Günthard H, Hirsch H, Egger M, Vernazza P, Bernasconi E, Telenti A, Ebnother C, Oxenius A et al., 2003. AIDS, 17 pp. 1487-1492.
[serval:BIB_27241]
 
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C., Oxenius A., Günthard H., Garcia F., Le Braz M., Mestre G., Battegay M., Furrer H., Vernazza P., Bernasconi E. et al., 2003. Archives of Internal Medicine, 163 (10) pp. 1220-1226.
[DOI][WoS][Pmid][serval:BIB_27240]
 
Anti-cytokine therapies in patients with severe sepsis and septic shock.
Bochud P.Y., Glauser M.P., Calandra T., 2003. pp. 381-408 dans Kotb M., Clandra T. (eds.) Cytokines and Chemokines in Infectious Diseases Handbook, Humana Press.
[serval:BIB_288DAA4F9B1C]
 
Antibiotic-dependent correlation between drug-induced killing and loss of luminescence in Streptococcus gordonii expressing luciferase.
Loeliger B., Caldelari I., Bizzini A., Stutzmann Meier P., Majcherczyk P.A., Moreillon P., 2003. Microbial Drug Resistance, 9 (2) pp. 123-131.
[DOI][WoS][Pmid][serval:BIB_33A8CA65928B]
 
Anticytokine therapies in patients with severe sepsis and septic shock.
Bochud P.Y., Glauser M.P., Calandra T., 2003. pp. 381-407 dans Kotb M, Calandra T (eds.) Cytokines and chemokines in infectious diseases handbook chap. 25, Humana Press.
[serval:BIB_6C1758B1EB1A]
 
Antivirale Therapie und Resistenzentwicklung am Beispiel der HIV-Infektion.
Furrer H, Telenti A, 2003. Therapeut Umschau, 60 pp. 631-625.
[serval:BIB_27248]
 
Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence.
Sanglard D., Ischer F., Marchetti O., Entenza J., Bille J., 2003. Molecular Microbiology, 48 (4) pp. 959-976.
[DOI][WoS][Pmid][serval:BIB_972BB8241B89]
 
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann G.R., Perrin L., Pantaleo G., Opravil M., Furrer H., Telenti A., Hirschel B., Ledergerber B., Vernazza P., Bernasconi E. et al., 2003. Archives of Internal Medicine, 163 (18) pp. 2187-2195.
[DOI][WoS][Pmid][serval:BIB_27245]
 
Closing the gap: mortality in the Swiss HIV Cohort Study compared to the Swiss reference population.
Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, Furrer HJ, Telenti A, Battegay M, Flepp M et al., 2003. Lancet, 362 pp. 877-888.
[serval:BIB_27239]
 
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling.
Bochud P.Y., Hawn T.R., Aderem A., 2003. Journal of Immunology, 170 (7) pp. 3451-3454. Peer-reviewed.
[WoS][Pmid][serval:BIB_646030DFF2C6]
 
Cytokines and Chemokines in Infectious Diseases Handbook.
Kotb M Calandra T. (eds.)Kotb M Calandra T., 2003., Humana Press.
[serval:BIB_5AE18E834C8D]
 
Diagnosis and management of metabolic complications of HIV therapy.
Bernasconi E., Tebas P., Telenti A., 2003. pp. 49-68 dans Infection, Bouza E..
[serval:BIB_27445]
Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups
Bennett J.E., Kauffman C., Walsh T., de Pauw B., Dismukes W., Galgiani J., Glauser M., Herbrecht R., Lee J., Pappas P. et al., 2003. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 36 (Suppl 3) pp. S123-S127.
[URN][DOI][WoS][Pmid][serval:BIB_EE7E186FEA50]
 
Fungicidal synergism of fluconazole and cyclosporin in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1 and FLU1 genes.
Marchetti O, Moreillon P, Vouillamoz J, Entenza JM, Glauser MP, Bille J, Sanglard D, 2003. Antimicrob Agents Chemother, 47 pp. 1565-1570.
[serval:BIB_26783]
 
Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes.
Marchetti O., Moreillon P., Entenza J.M., Vouillamoz J., Glauser M.P., Bille J., Sanglard D., 2003. Antimicrobial Agents and Chemotherapy, 47 (5) pp. 1565-1570.
[DOI][WoS][Pmid][serval:BIB_C1A5CCC317C2]
 
Génétique humaine et VIH
Ciuffi A., Bleiber G., Telenti A., 2003. Médecine et Hygiène, 61 (2453) pp. 1926-1928.
[serval:BIB_F4A687DC9A93]
 
High frequency of alternative splicing of human genes participating in the HIV-1 life cycle - a model using Tsg101, bTrCP, PPIA, INI1, NAF1 and PML.
Favre M, Butticaz C, Stevenson B, Jongenneel CV, Telenti A, 2003. JAIDS, 34 pp. 127-133.
[serval:BIB_27243]
 
Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.
Trkola A., Kuster H., Leemann C., Ruprecht C., Joos B., Telenti A., Hirschel B., Weber R., Bonhoeffer S., Günthard H.F., 2003. Journal of virology, 77 (24) pp. 13146-55. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7D7067051FB7]
 
Infections in the Immunocompromised Patient
Calandra T, SH Holland (eds.)Calandra T, SH Holland, 2003., Cohen J, Powderly WG, Elsevier Science.
[serval:BIB_569FD5522D74]
 
Infections in the neutropenic cancer patient
Marchetti O., Calandra T., 2003. 15.
[serval:BIB_2FB11EAC5310]
 
Infections in the neutropenic cancer patient.
Marchetti O, Calandra T, 2003. pp. 1077-1092 dans Infectious Diseases, 2nd Edition.
[serval:BIB_26790]
 
Infections in the neutropenic cancer patient.
Marchetti O., Calandra T., 2003. pp. 1077-109 dans Cohen J, Powderly W.G (eds.) Infectious Diseases chap. 1077-109, Elsevier Science.
[serval:BIB_838750E6D5B6]
 
Infections in the neutropenic cancer patient. Section 4 (Infections in the immunocompromised host)
Marchetti O., 2003. pp. 1077-1092 dans Infectious Diseases chap. 102, Mosby.
[serval:BIB_14D344086507]
Introduction the Forum Report on Advances in the Design of Antifungal Clinical Trials
Bennett John E., de Pauw Ben, Dismukes William, Galgiani John, Glauser Michel, Herbrecht Raoul, Kauffman Carol, Lee Jeannette, Pappas Peter, Powers John et al., 2003. Clinical Infectious Diseases, 36 (Supplement_3) pp. S112-S112.
[URN][DOI][WoS][serval:BIB_5D67431B1DC1]
Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
Eigenmann C., Flepp M., Bernasconi E., Schiffer V., Telenti A., Bucher H., Wagels T., Egger M., Furrer H., Swiss HIV Cohort Study, 2003. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 36 (7) pp. 917-921. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_27237]
 
Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4).
Roger T., Froidevaux C., Martin C., Calandra T., 2003. Journal of Endotoxin Research, 9 (2) pp. 119-123. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FB1FD57C4BD3]
Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis.
Calandra T., Froidevaux C., Martin C., Roger T., 2003. The Journal of infectious diseases, 187 Suppl 2 pp. S385-90. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_19D02A04C9E2]
 
Macrophage migration inhibitory factor and host innate immune responses to microbes
Calandra T., 2003. Scandinavian Journal of Infectious Diseases, 35 (9) pp. 573-6.
[DOI][WoS][Pmid][serval:BIB_95B04B3EC0D5]
 
Macrophage migration inhibitory factor and host innate immune responses to microbes.
Calandra T, 2003. Scandinavian Journal of Infectious Diseases, 35 pp. 573-576.
[serval:BIB_26802]
 
Macrophage migration inhibitory factor as a cytokine of innate immunity.
Calandra T., 2003. pp. 65-74 dans Kotb M, Calandra T (eds.) Cytokines and chemokines in infectious diseases handbook chap. 5, Humana Press.
[serval:BIB_36AC8230D4A3]
Macrophage migration inhibitory factor: a regulator of innate immunity.
Calandra T., Roger T., 2003. Nature reviews. Immunology, 3 (10) pp. 791-800. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2CA3902B3091]
 
Pathogenesis of sepsis: new concepts and implications for future treatment.
Bochud P.Y., Calandra T., 2003. BMJ (Clinical research ed.), 326 (7383) pp. 262-6.
[DOI][WoS][Pmid][serval:BIB_7529C938E282]
 
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39A9FD8E09B3]
 
Prevalence of unsafe sexual behaviour among HIV-infected individuals: The Swiss HIV Cohort Study .
Wolf K, Young J, Rickenbach M, Vernazza P, Flepp M, Furrer H, Bernasconi E, Hirschel B, Telenti A, Weber R et al., 2003. JAIDS, 33 pp. 494-499.
[serval:BIB_27242]
 
Prise en charge de la neutropénie fébrile à bas risque
Cometta A., Marchetti O., Calandra T., 2003. Swiss Medical Forum = Forum Médical Suisse, 3 (6) pp. 124-129.
[serval:BIB_0A2D5719712A]
Response to van Saene et al.'s comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients".
Calandra T., Marchetti O., 2003. Intensive care medicine, 29 (7) p. 1196. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6AFD1B34148]
 
Teichoic acids are not required for Streptococcus pneumoniae and Staphylococcus aureus cell walls to trigger the release of tumor necrosis factor by peripheral blood monocytes.
Majcherczyk P.A., Rubli E., Heumann D., Glauser M.P., Moreillon P., 2003. Infection and Immunity, 71 (7) pp. 3707-3713.
[DOI][WoS][Pmid][serval:BIB_67B0F27A67E8]
 
The stereochemistry of the amino acid side chain influences the inflammatory potential of muramyl dipeptide in experimental meningitis.
Cottagnoud P., Gerber C.M., Majcherczyk P.A., Acosta F., Cottagnoud M., Neftel K., Moreillon P., Täuber M.G., 2003. Infection and Immunity, 71 (6) pp. 3663-3666.
[DOI][WoS][Pmid][serval:BIB_EF442FB2AEC6]
 
Traitement des infections invasives à Candida et Aspergillus : quoi de neuf en 2003 ?
Marchetti O., Calandra T., 2003. Médecine et Hygiène, 61 (2431) pp. 701-706.
[serval:BIB_62722B3B6C11]
 
www.fevertravel.ch : site internet de recommandations pour la pratique clinique concernant l'évaluation de la fièvre chez les voyageurs et migrants [www.fevertravel.ch: a website for the evaluation and management returning travelers or migrants with fever]
D'Acremont V., Ambresin A.E., Pittet V., Burnand B., Genton B., 2003. Médecine et Hygiène, 61 (2437) pp. 1022-1026.
[serval:BIB_6C80B38C1801]
2002
 
Disseminated histoplasmosis in Switzerland: an unexpected cause of septic shock and multiple organ dysfunction
Cavassini M., Lepori M., Baur A. S., Bille J., Schaller M. D., Marchetti O., 2002/10. Intensive Care Medicine, 28 (10) pp. 1501-2.
[DOI][WoS][Pmid][serval:BIB_435AF64EB12D]
 
Initial responses to endotoxins and Gram-negative bacteria
Heumann D., Roger T., 2002/09. Clinica Chimica Acta, 323 (1-2) pp. 59-72.
[DOI][WoS][Pmid][serval:BIB_1BAA41567071]
 
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection
Harari A., Rizzardi G. P., Ellefsen K., Ciuffreda D., Champagne P., Bart P. A., Kaufmann D., Telenti A., Sahli R., Tambussi G. et al., 2002/08. Blood, 100 (4) pp. 1381-7.
[DOI][WoS][Pmid][serval:BIB_A47337CF723B]
Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial.
Pagani J.L., Chave J.P., Csajka C., Glauser M.P., Bille J., 2002/08. The Journal of antimicrobial chemotherapy, 50 (2) pp. 231-240. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_63978C9C55C1]
 
Evidence for a role of the nerve growth factor receptor TrkA in tyrosine phosphorylation and processing of beta-APP
Tarr P. E., Contursi C., Roncarati R., Noviello C., Ghersi E., Scheinfeld M. H., Zambrano N., Russo T., D'Adamio L., 2002/07. Biochemical and Biophysical Research Communications, 295 (2) pp. 324-9. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4BB28CDF8D1E]
 
Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc.
Tarr P.E., Roncarati R., Pelicci G., Pelicci P.G., D'Adamio L., 2002/05. Journal of Biological Chemistry, 277 (19) pp. 16798-16804. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_19289715A6BA]
 
Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease
Lue H., Kleemann R., Calandra T., Roger T., Bernhagen J., 2002/04. Microbes and Infection, 4 (4) pp. 449-60.
[DOI][WoS][Pmid][serval:BIB_69373A259847]
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes W. T., Armstrong D., Bodey G. P., Bow E. J., Brown A. E., Calandra T., Feld R., Pizzo P. A., Rolston K. V., Shenep J. L. et al., 2002/03. Clinical Infectious Diseases, 34 (6) pp. 730-51.
[URN][DOI][WoS][Pmid][serval:BIB_594554FB7BED]
 
1992-1995
Calandra T Bucala R., 2002. pp. 1992-1995 dans Calandra T Bucala R. (eds.) Macrophage migration inhibitory factor (MIF)., John Wiley and Sons, Inc..
[serval:BIB_B49AD31BD77F]
 
Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs.
Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M et al., 2002. JAIDS, 21 pp. 50-55.
[serval:BIB_24759]
 
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.
Harari A, Rizzardi GP, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Kaufmann D, Telenti A, Sahli R, Tambussi G et al., 2002. Blood, 100 pp. 1381-1387.
[serval:BIB_24756]
 
Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure.
Telenti A., Martinez R., Munoz M., Bleiber G., Greub G., Sanglard D., Peters S., 2002. Journal of virology, 76 (15) pp. 7868-73. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BA650DBF4A6D]
 
Antifungal prophylaxis for intensive care unit patients: let's fine tune it.
Calandra T., Marchetti O., 2002. Intensive care medicine, 28 (12) pp. 1698-1700. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_44BFF3199418]
 
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphyloccocus aureus in treatment of experimental endocarditis.
Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P, 2002. Antimicrob Agents Chemother, 46 pp. 171-177.
[serval:BIB_24701]
 
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.
Entenza J.M., Hohl P., Heinze-Krauss I., Glauser M.P., Moreillon P., 2002. Antimicrobial Agents and Chemotherapy, 46 (1) pp. 171-177.
[DOI][WoS][Pmid][serval:BIB_64C274A88A2E]
 
Cytokines in septic shock.
Calandra T., Bochud P.Y., Heumann D., 2002. Current clinical topics in infectious diseases, 22 pp. 1-23.
[Pmid][serval:BIB_22704]
 
Does Switzerland train tomorrow's surgeons today? Today's reflections on tomorrow's surgeons.
Schäfer M., Harder Y., Keel M., Kulli C.h., Müller C., Perret A., Saucy F., Vallet C., 2002. Swiss Surgery, 8 (3) pp. 103-105.
[Pmid][serval:BIB_54D88428CC7A]
 
Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.
Doser N., Kübli S., Telenti A., Marzolini C., Chave J.P., Feihl F., Buclin T., Pannatier A., Darioli R., Nicod P. et al., 2002. AIDS, 16 (14) pp. 1982-3. Peer-reviewed.
[Pmid][serval:BIB_477361CA79FF]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University